Immunitybio, inc. announces pricing of public offering of common stock

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. immunitybio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. all of.
IBRX Ratings Summary
IBRX Quant Ranking